Sharon Osbourne has decided to completely forgo weight loss routines and cosmetic procedures after a medication left her stuck losing weight and unable to keep any on. The drug Ozempic gained national attention when cultural icons like Osbourne, Elon Musk, Amy Schumer, and others touted the drug, prescribed for diabetes, as a weight-loss aid. Osbourne, however, is done with the injectible.
Osbourne also pursued a facelift three years ago but that ended in a different kind of disaster. She likened her final appearance to that of a cyclops and called the cosmetic procedure the “worst thing” she’d ever done. Here are her plans instead.
Sharon Osbourne is feeling the side effects of Ozempic
Last year, Osbourne spoke with the Daily Mail to warn those interested in Ozempic for weight loss to “be careful what you wish for.”
RELATED: Sharon Osbourne Admits She Sometimes Goes Up To Three Days Without Eating
“You can lose so much weight, and it’s easy to become addicted to that, which is very dangerous,” she shared. “I couldn’t stop losing weight, and now I’ve lost 42 pounds, and I can’t afford to lose any more.”
She went on, “I started on Ozempic last December, and I’ve been off it for a while now, but my warning is don’t give it to teenagers; it’s just too easy.”
The consequences are popping up
Ozempic was approved of for the treatment of diabetes first and foremost back in December 2017. Ozempic is a kind of semaglutide, a medication prescribed for type 2 diabetes. It is sold under the brand names Rybelsus and Ozempic. Typically, Ozempic will be prescribed in conjunction with diet and exercise to control elevated blood glucose levels; it generally works by suppressing appetite and typically has side effects like nausea and diarrhea.
Because of this function – and even the side effects – Ozempic became popular among high-profile personalities to take as a road to weight loss, even without a type 2 diabetes diagnosis.
Last year marked a nationwide shortage of Ozempic and other injections prescribed for those with diabetes because of the celebrity endorsements as a weight loss tool exclusively. Mounjaro met a similar fate as Ozempic. As noted by Omnia Health, celebrity endorsement can encourage drug companies to produce more of a product but will also lead to growing pains when there is an imbalance in supply and demand; this, the outlet notes, “can be challenging for those who rely on the medication for medical purposes rather than just losing weight.”
Shortages also took place back in 2022, to the point that Danish drug manufacturer Novo Nordisk had to address the disruption some patients would endure. “While we recognize that some healthcare providers may be prescribing Ozempic for patients whose goal is to lose weight,” the company said to Fox News Digital in a statement, “it is up to the clinical discretion of each healthcare provider to choose the best treatment approach for their patients.”
In fact, over in Australia, Ozempic was totally unavailable from November 2022 to the end of March 2023.
